“…In this context, elevated RCAS1 expression, as assessed by immunohistochemistry, has been reported in the tumor malignant stage of several organs, including the uterus [6], skin [7], liver [8], gall bladder [9], stomach [10], lung [11], colon [12,13], breast [14], esophagus [15], and pancreas [16]. RCAS1 expression has also been found to be correlated with important clinicopathological parameters and with patient survival in several of these malignant tumors; as such, it has been considered to be an indicator of poor prognosis.…”